Review of discount rate in the PBAC guidelines
Page last updated: 25 May 2022
The Commonwealth has entered into a new Strategic Agreement in relation to reimbursement, health technology assessment and other matters (the Agreement) with Medicines Australia acting on behalf of the innovator medicines industry.
The Agreement includes a commitment to seek the advice of the Pharmaceutical Benefits Advisory Committee (PBAC) as to whether the base case discount rate at 3A.1 of the PBAC guidelines aligns with international best practice.
The PBAC will use a two-phased consultation approach to inviting input on the review of the discount rate.
The first phase of this consultation is closed. The second phase of this consultation is opened.
If you would like to make a submission or find further information about the PBAC’s consideration of the discount rate, please visit the Office of Health Technology Assessment Consultation Hub.
The PBAC intends to decide its advice at its July 2022 meeting.